非小细胞肺癌患者射频消融治疗后血清miR-28-3p表达量变化及意义

Changes and significance of serum miRNA-28-3p expression in patients with non-small cell lung cancer after radiofrequency ablation

目的探讨非小细胞肺癌(NSCLC)患者射频消融(RFA)治疗后血清miR-28-3p表达量变化及意义。方法选取2013年7月至2015年7月治疗的73例NSCLC患者为研究对象。采用RT-qPCR法检测患者治疗前后血清miR-28-3p相对表达量。分析血清miR-28-3p相对表达量与NSCLC患者预后的关系。结果NSCLC患者RFA治疗前血清miR-28-3p相对表达量为(12.62±2.51),经RFA治疗后血清miR-28-3p相对表达量降低[(10.46±2.10),P<0.05]。73例NSCLC患者3年生存率为61.6%(45/73)。NSCLC生存组患者血清miR-28-3p相对表达量明显低于死亡组患者(P<0.05)。血清miR-28-3p评估NSCLC患者生存预后的曲线下面积(AUC)为0.782。血清miR-28-3p≥11.05的NSCLC患者3年平均总生存时间为27.78(95%CI为24.30~31.27)个月,明显低于血清miR-28-3p<11.05的NSCLC患者3年总生存时间33.19(95%CI为30.84~35.55)个月,差异有统计学意义(P<0.05)。COX单因素及多因素回归分析显示年龄、TNM分期、肿瘤直径、淋巴结转移、miR-28-3p与NSCLC患者RFA后生存时间密切相关。结论NSCLC患者RFA后血清miR-28-3p相对表达量明显降低。血清miR-28-3p与RFA治疗后NSCLC患者生存预后密切相关。

Objective To investigate the changes of serum miRNA-28-3p expression in patients with non-small cell lung cancer(NSCLC)after radiofrequency ablation(RFA),and to discuss its clinical significance. Methods A total of 73 patients with NSCLC,who were treated with RFA during the period from July 2013 to July 2015,were selected as the subjects of study.The relative expressions of serum miRNA-28-3p before and after treatment were tested by RT-qPCR method.The correlation between the relative expressions of serum miRNA-28-3p and the prognosis of patients was analyzed.Results In NSCLC patients,the pre-RFA relative expression of serum miRNA-28-3p was (12.62±2.51) and the post-RFA relative expression of serum miRNA- 28-3p decreased to (10.46 ±2.10),the difference was statistically significant (P<0.05).In the 73 NSCLC patients the 3-year survival rate was 61.64%(45/73).The relative expression of serum miRNA-28-3p in the patients of survival group was significantly lower than that in the patients of death group (P<0.05).The AUC of serum miRNA-28-3p in evaluating survival and prognosis of NSCLC patients was 0.782.The mean 3-year survival time in NSCLC patients with serum miRNA-28-3p≥11.05 was 27.78 months (95% CI: 24.30-31.27 months),which was significantly lower than 33.19 months (95% CI:30.84-35.55 months) in NSCLC patients with serum miRNA-28-3p <11.05,the difference in 3-year survival time between the two groups was statistically significant(P<0.05).Univariate and multivariate COX regression analysis showed that age,TNM stage,tumor diameter,lymph node metastasis,and miRNA-28-3p were closely related to the survival time of NSCLC patients after RFA.Conclusion After RFA,the relative expression of serum miRNA-28-3p in NSCLC patients is significantly decreased.Serum miRNA-28-3p is closely related to the survival and prognosis of NSCLC patients after RFA.